C4X to quit stock market and seek venture funding for drug discovery
Languishing share price and high cost of regulatory burden of AIM listing makes decision a no-brainer
Source: thebusinessdesk.com
Stay updated with breaking news from Antagonist Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Languishing share price and high cost of regulatory burden of AIM listing makes decision a no-brainer
C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior ...